Do you continue calcium channel blocker monotherapy in a patient with idiopathic PAH who had an acute vasoreactive response at diagnosis and achieved WHO functional class I or II at 12 months, or would you still add disease modifying therapy with sotatercept?

This is a data-free zone. However, given that many patients who are calcium channel blocker responsive often normalize or near-normalize their hemodynamics, there often is no need to add additional therapies. Most PH clinicians would increase the calcium channel dose prior to switching or adding cla...